Get Started

Artificial Intelligence | Machine Learning Immunitas Therapeutics | Immuno-oncology Therapeutics Company

Consumer, Biotechnology, Drug Discovery, Antibodies, Therapy Onboarding, Therapeutic Evaluation, Drug Developm Cambridge , Massachusetts, United States

Artificial Intelligence | Machine Learning

Immunitas Therapeutics | Immuno-oncology Therapeutics Company

Biotechnology, Drug Discovery, Antibodies, Therapy Onboarding, Therapeutic Evaluation, Drug Developm

Cambridge , Massachusetts, United States

Immunitas is an immuno-oncology therapeutics company advancing multiple programs to the clinic. Immunitas’ programs are derived from a cross-functional, highly integrated, single cell genomics platform that enables rapid target identification and validation in parallel with antibody discovery and engineering. IMT-009, a first-in-class T & NK cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. The company was founded with leading scientists from Dana Farber, MGH, the Broad, and MIT. In 2019, Immunitas raised a $39M Series A from a strong syndicate of investors including the Longwood Fund, Hillhouse, NVF, Leaps by Bayer, and M Ventures.

Total Funding: N/A

Funding Stage: N/A

Business Stage: Scaling Up

Market: B2C

Company Size: 26 to 50

Founded: 2019

Nov 2021

Immunitas Therapeutics Names Amanda Wagner as CEO

Sep 2021

Immunitas Therapeutics Appoints Seng-Lai ‘Thomas’ Tan, Ph.D. as Chief Scientific Officer

Date

Round

$ Raised

Investors

08/18/2021

Series B

$58M

Ono Venture Investment, Novartis Venture Fund (NVF), NS Investment, M Ventures, Mirae Asset, Medical Excellence Capital, Longwood Fund, The Leukemia & Lymphoma Society Therapy Acceleration Program, Evotec, Agent Capital, 120 Capital

Date : 08/18/2021

Round: Series B

$ Raised: $58M

Investors: Ono Venture Investment, Novartis Venture Fund (NVF), NS Investment, M Ventures, Mirae Asset, Medical Excellence Capital, Longwood Fund, The Leukemia & Lymphoma Society Therapy Acceleration Program, Evotec, Agent Capital, 120 Capital

For AI/ML Startup Founders

Get introduced to VC/PE/CVC investors

Signup and Get Started

For Investors at VC/PE firms

Get introduced to AI/ML Startup founders or founders at Immunitas Therapeutics

Amanda Wagner
CEO

Seng-Lai "Thomas" Tan
Chief Scientific Officer

Ming Tang
Director of Computational Biology

Char Gross
Head of HR

Jeff D Colbert
Immunologist

Immunitas Therapeutics - Manage Profile

Immunitas Therapeutics is growing. Want to work at Immunitas Therapeutics? Immunitas Therapeutics is hiring. Join team at Immunitas Therapeutics

World's Most Promising AI/ML Startups